New AI platform to help with paperwork process launching through NS Health
The Nova Scotia Health Innovation Hub hosted a launch on Wednesday evening for an AI-powered platform called 'ImmigrateAI Global.'
The app will improve wait times by simplifying the paperwork involved with the immigration process for health-care workers, skilled tradespeople and international talent across the country.
'Health-care workers are stuck doing immigration paperwork when instead they could be contributing to our beautiful province taking care of patients,' said Max Medyk, CEO of ImmigrateAI Global. 'And were here to make sure it happens with AI.'
Jill Balser, Cyber Security and Digital Solutions minister, said the app will help with retaining health-care workers and skilled tradespeople in the province.
For more Nova Scotia news, visit our dedicated provincial page
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case
NanoViricides, Inc. (NYSE Amer.: NNVC), a clinical-stage biopharmaceutical company and a pioneer in broad-spectrum antivirals, announced today its accelerated plans to advance its lead drug candidate, NV-387, into Phase II clinical trials for MPox. This strategic decision positions the company to potentially bring a much-needed antiviral to market faster, addressing a critical global health need while also paving the way for further pipeline development. NanoViricides highlighted several key reasons for prioritizing MPox as the first indication for NV-387's Phase II development, even with strong efficacy data in animal studies for other major viral threats like RSV, Influenza, and COVID. Strategic Advantages of the MPox Focus The company believes its focus on MPox offers significant advantages: Urgent Need and Timely Trial Completion: With a continuing MPox epidemic in the African Region, there's a pressing demand for effective treatments. This also facilitates patient recruitment, enabling a more rapid completion of the clinical trial. Cost-Effectiveness: Conducting clinical trials in the African Region is substantially more economical compared to the US or Europe, allowing NanoViricides to optimize its research budget. Validation of Animal Model Data: A successful Phase II trial for MPox in humans would validate the company's use of lethal challenge animal models. This is a critical point, as NanoViricides' animal studies have consistently shown NV-387 to be significantly superior to existing drugs across all tested infections. Strong Financial and Public Health Case: The recent failure of tecovirimat (Tpoxx) in MPox clinical trials creates a clear void in the US Strategic National Stockpile (SNS) for effective antivirals against orthopoxviruses like MPox and Smallpox. Both tecovirimat and brincidofovir (Tembexa), currently approved for Smallpox under the "FDA Animal Rule," have shown limitations. Brincidofovir failed due to liver toxicity, and tecovirimat demonstrated no superiority over standard care. NanoViricides believes NV-387 could become a crucial addition to the SNS, potentially securing substantial initial acquisition contracts. Addressing a Critical Vulnerability: Unlike small chemical drugs that viruses can readily escape through mutations, NanoViricides' host-mimetic nanomedicine technology is designed to make it difficult for viruses to develop resistance. This is particularly important for bioterrorism readiness, as manipulated forms of viruses like Smallpox could be engineered to resist conventional treatments. The company emphasizes the strong case for the US Department of Health and Human Services (HHS) to support NV-387 development for bioterrorism preparedness. Innovative Drug Delivery Adding to its strategic advantages, NV-387 will be administered as "NV-387 Oral Gummies." This soft solid formulation is designed to dissolve naturally in the oral cavity, eliminating the need for swallowing pills or capsules. This is a significant benefit for MPox patients who often suffer from painful oral lesions, making swallowing difficult. Addressing the Broader MPox Threat The ongoing MPox epidemic in the Democratic Republic of Congo (DRC) is driven by Clade 1a and the more transmissible Clade 1b subtypes, which have higher case fatality rates than the Clade 2b circulating in the Western world. While sporadic Clade 1 cases have been reported in the USA without further spread, the potential for a larger epidemic cannot be ignored. NanoViricides asserts that readiness with an effective drug against Clade 1 MPox is crucial for national health security. NanoViricides, Inc. is a publicly traded clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. The company's innovative nanoviricide™ class of drug candidates is based on technology and proprietary know-how from TheraCour Pharma, Inc. Other notable stocks to keep on top of radar include Summit Therapeutics (SMMT), Regulus Therapeutics (RGLS), Vigil Neuroscience (VIGL), Alaunos Therapeutics (TCRT), CervoMed Inc. (CRVO), Niagen Bioscience (NAGE) and Beam Therapeutics (BEAM). Source: Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or an endorsement of BURU or its strategies. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Please ensure to fully read and comprehend our disclaimer found at has been compensated fifteen hundred dollars by a 3rd party EDM Media Consulting Group for content distribution services on nnvc or July 6th, 2025. is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like 'believes,' 'anticipates,' 'estimates,' 'expects,' 'projects,' 'intends,' or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at It is always important to conduct thorough due diligence and exercise caution in is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated. Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. is not a fiduciary by virtue of any person's use of or access to this content. This article is for informational purposes only and does not constitute investment advice. Always conduct your own research before making investment decisions. This analysis represents the opinion of the author based on publicly available information and should not be considered investment advice. Investors should conduct their own due diligence before making investment decisions. Media Contact Company Name: UsaStockReport Contact Person: Ash K Email: editor@ City: Frisco State: Texas Country: United States Website:
Globe and Mail
31 minutes ago
- Globe and Mail
Canada's emergency room crisis is worse than we thought
Ever since the pandemic, emergency-room closures have become more common in Canada, especially in rural communities. This can leave people in dangerous situations that can require them to drive an hour or more to access emergency medical care. When time is of the essence, emergency-room closures can be deadly. Because there's no centralized data on how common closures are across Canada, it's challenging to parse out how bad the problem is. As part of The Globe's Secret Canada series, health reporter Kelly Grant, investigative reporter Tu Thanh Ha and data editor Yang Sun analyzed data on emergency room closures across Canada. Kelly and Ha are on the show to talk about how widespread these closures really are, what it means for people living in those communities and what kinds of solutions are possible. Questions? Comments? Ideas? Email us at thedecibel@
CBC
an hour ago
- CBC
Temporary housing unaffordable for organ transplant patients, say charities
Two charities that help organ transplant patients in Edmonton and Toronto say it's time that provincial governments rethink the way they offer housing support for patients who must temporarily move to access treatment. Their comments come after some Nova Scotia lung transplant patients started campaigning for more funding, saying people are selling their homes in order to get life-saving health care. It's a story Silvio Dobri has heard over and over again. He had a heart transplant nearly 30 years ago and has dedicated his life to paying it forward ever since. Dobri founded the GoodHearts Transplant Foundation in Edmonton, which now offers eight apartments near the University of Alberta Hospital at a subsidized rate to transplant patients. The patients pay $40 a day for the furnished apartment, don't have to pay a deposit and don't have to give any notice when they're leaving. "For me, it's really important that we keep this up for as long as we can," Dobri said. Dobri still gets emotional talking about his experience. A donor heart became available just one day after he was placed on the transplant list. "I was really grateful to get a heart that quickly." As he recovered at the University of Alberta Hospital, he met other patients who were facing another stress — paying for their accommodations. Anyone who needs an organ must stay near a major hospital while they receive their life-saving care, with that care often stretching on for months. Jackie Foord, the current CEO of GoodHearts, says patients across Canada are struggling to find apartments near hospitals in the midst of a national housing crisis, putting extra stress on patients in critical situations. "Travelling in Canada for what I would call specialized health care is a real issue for so many people," Foord said. "It is a tremendous burden." In Nova Scotia, lung transplant families have started speaking out about that financial burden. Transplant patients receive $3,000 a month from the province to cover their rent in Toronto, where they must live with a caregiver for months. Verbena Brenton-Goguen said expenses were so high while her late husband received his transplant that she now has to sell their family home in Springhill, N.S. Nan and Dave Clarke told CBC the cheapest furnished apartment they could find while they were in Toronto for her double lung transplant cost $5,900 a month. That doesn't surprise Sass Khazzam at all. He runs StayWell Toronto, a charity that negotiates with hotels and apartment companies near the hospitals in Toronto to provide patients with affordable accommodations. Khazzam said $3,000 a month won't cover the cost of a one-bedroom furnished apartment, even with the charity's rates. He said patients don't have any choice about the timing of their visit and sometimes show up during peak tourist seasons, when costs are even more prohibitive. "When we had, for example, Taylor Swift here, accommodation rates went up to $2,000 a night. Next summer we have FIFA [soccer] coming, and we'll have the same problem." Khazzam said StayWell does its best to further subsidize rooms in those situations to try to make stays affordable. He said most of the families the organization assists are from Ontario, but this year, more than 10 per cent of them have been from Atlantic Canada. Khazzam said the charity sometimes has to turn people away because even with their connections, they can't find appropriate available spots. Right now, for example, they have no monthly availability until August, he said. "I appreciate that governments can only do so much, but there's always room for more," he said. "People need help. We do the best we can." Each province and territory has its own approach to living expenses for transplant patients. Some, including Alberta, don't offer anything to patients who have to move away for treatment. New Brunswick just increased its monthly allowance to $4,000. Michelle Thompson, Nova Scotia's health minister, told CBC in June that her department has numerous requests for financial help with health care, and the money can only go so far. Foord said the disparity is unfair. "It might be time for governments to talk about access to rural and remote communities because everyone deserves health care," she said. "Not being able to access it is so devastating for so many people."
